These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35765939)

  • 1. IMPACT study: Impact of adherence to anti-VEGF intravitreal injections for macular disease during COVID 19-related confinement in France.
    Hurand V; Ducloyer JB; Baudin F; Aho S; Weber M; Kodjikian L; Devin F; Gabrielle PH; Creuzot-Garcher C; Massin P;
    Acta Ophthalmol; 2023 Feb; 101(1):91-99. PubMed ID: 35765939
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term impact of delayed follow-up due to COVID-19 lockdown on patients with neovascular age-related macular degeneration.
    Szegedi S; Ebner C; Miháltz K; Wachter T; Vécsei-Marlovits PV
    BMC Ophthalmol; 2022 May; 22(1):228. PubMed ID: 35596203
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The importance of monitoring wet age-related macular degeneration patients during Coronavirus disease 19 pandemic: A retrospective study of assessment of functional and structural outcomes.
    Tsiropoulos GN; Vallee R; Gallo Castro D; Ambresin A
    J Fr Ophtalmol; 2022 Oct; 45(8):852-859. PubMed ID: 35908993
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome of Patients Treated by Intravitreal Injections During the COVID-19 Lockdown: An Institutional Experience.
    Sukkarieh G; Bonnin S; Azar G; Lafolie J; Alonso AS; Erol O; Pineau J; Villain H; Guillaume J; Auge E; Mingou A; Lejoyeux R; Vasseur V; Mauget-Faÿsse M
    Curr Eye Res; 2023 Jul; 48(7):683-689. PubMed ID: 37024478
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Impact of the French 2020 COVID-19 lockdown on the treatment and follow-up of patients with exudative age-related macular degeneration].
    Auger A; Khanna RK; Bonicel P; Pisella PJ; Le Lez ML
    J Fr Ophtalmol; 2023 Jun; 46(6):596-604. PubMed ID: 37248127
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delaying anti-VEGF therapy during the COVID-19 pandemic: long-term impact on visual outcomes in patients with neovascular age-related macular degeneration.
    Nassisi M; Pozzo Giuffrida F; Milella P; Ganci S; Aretti A; Mainetti C; Dell'Arti L; Mapelli C; Viola F
    BMC Ophthalmol; 2023 Apr; 23(1):156. PubMed ID: 37069537
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The effect of COVID-19 pandemic restrictions on neovascular AMD patients treated with treat-and-extend protocol.
    Sevik MO; Aykut A; Özkan G; Dericioğlu V; Şahin Ö
    Int Ophthalmol; 2021 Sep; 41(9):2951-2961. PubMed ID: 33864577
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of a calculation model to estimate the impact of the COVID-19 pandemic lockdown on visual acuity in neovascular AMD.
    Stattin M; Haas AM; Ahmed D; Graf A; Krepler K; Ansari-Shahrezaei S
    Eur J Ophthalmol; 2022 Jul; 32(4):2312-2318. PubMed ID: 34726553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predicting the immediate impact of national lockdown on neovascular age-related macular degeneration and associated visual morbidity: an INSIGHT Health Data Research Hub for Eye Health report.
    Mollan SP; Fu DJ; Chuo CY; Gannon JG; Lee WH; Hopkins JJ; Hughes C; Denniston AK; Keane PA; Cantrell R
    Br J Ophthalmol; 2023 Feb; 107(2):267-274. PubMed ID: 34518162
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Real-World Effectiveness and Real-World Cost-Effectiveness of Intravitreal Aflibercept and Intravitreal Ranibizumab in Neovascular Age-Related Macular Degeneration: Systematic Review and Meta-Analysis of Real-World Studies.
    Carrasco J; Pietsch GA; Nicolas MP; Koerber C; Bennison C; Yoon J
    Adv Ther; 2020 Jan; 37(1):300-315. PubMed ID: 31728825
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment patterns and visual acuity change of AMD patients, before, during and after the COVID-19 pandemic lockdowns: A large cohort.
    Barequet D; Shor R; Segal O; Greenbaum E; Trivizki O; Loewenstein A; Rabina G
    Acta Ophthalmol; 2024 May; 102(3):e322-e327. PubMed ID: 37698269
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Management and Outcomes for Neovascular Age-Related Macular Degeneration: Analysis of United States Electronic Health Records.
    Kiss S; Campbell J; Almony A; Shih V; Serbin M; LaPrise A; Wykoff CC
    Ophthalmology; 2020 Sep; 127(9):1179-1188. PubMed ID: 32345477
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intravitreal Dexamethasone as a Rescue for Anti-Vascular Endothelial Growth Factor Therapy in Neovascular Age-Related Macular Degeneration with Persistent Disease Activity and High Treatment Demand.
    Pietzuch M; Mantel I; Ambresin A; Tappeiner C; Nagyova D; Donati G; Pfister IB; Schild C; Garweg JG
    J Ocul Pharmacol Ther; 2024; 40(6):361-369. PubMed ID: 38117666
    [No Abstract]   [Full Text] [Related]  

  • 14. Predictors of visual outcomes in patients with neovascular age-related macular degeneration treated with anti-vascular endothelial growth factor therapy: post hoc analysis of the VIEW studies.
    Lanzetta P; Cruess AF; Cohen SY; Slakter JS; Katz T; Sowade O; Zeitz O; Ahlers C; Mitchell P
    Acta Ophthalmol; 2018 Dec; 96(8):e911-e918. PubMed ID: 29659183
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macular Atrophy Incidence and Progression in Eyes with Neovascular Age-Related Macular Degeneration Treated with Vascular Endothelial Growth Factor Inhibitors Using a Treat-and-Extend or a Pro Re Nata Regimen: Four-Year Results of the MANEX Study.
    Spooner KL; Fraser-Bell S; Cozzi M; Staurenghi G; Invernizzi A; Monteduro D; Munk MR; Hong T; Chang AA
    Ophthalmology; 2020 Dec; 127(12):1663-1673. PubMed ID: 32544561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delayed anti-VEGF injections during the COVID-19 pandemic and changes in visual acuity in patients with three common retinal diseases: A systematic review and meta-analysis.
    Im JHB; Jin YP; Chow R; Dharia RS; Yan P
    Surv Ophthalmol; 2022; 67(6):1593-1602. PubMed ID: 35970234
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long Intervals between Intravitreal Injections Using a Treat-and-Extend Protocol in a Real-Life Context in AMD: The LIRE Study.
    Leroux P; Agard E; Billant J; Levron A; Bouvarel H; Badri Y; Douma I; Pradat P; Dot C
    Ophthalmologica; 2024; 247(1):44-57. PubMed ID: 38104545
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Retrospective Study of Ranibizumab Treatment Regimens for Neovascular Age-Related Macular Degeneration (nAMD) in Australia and the United Kingdom.
    Johnston RL; Carius HJ; Skelly A; Ferreira A; Milnes F; Mitchell P
    Adv Ther; 2017 Mar; 34(3):703-712. PubMed ID: 28144918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Real-life management of neovascular age-related macular degeneration (nAMD) in France: a nationwide observational study using retrospective claims data.
    Korobelnik JF; Delcourt C; Creuzot-Garcher C; Melaine A; Chassetuillier J; Lejeune A; Bénard S; Dupont-Benjamin L
    J Med Econ; 2021; 24(1):1087-1097. PubMed ID: 34420480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Macula service evaluation and assessing priorities for anti-VEGF treatment in the light of COVID-19.
    Stone LG; Devenport A; Stratton IM; Talks JS
    Graefes Arch Clin Exp Ophthalmol; 2020 Dec; 258(12):2639-2645. PubMed ID: 32712708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.